Investigation the effect of oleoylethanolamide supplementation on the abundance of Akkermansia muciniphila bacterium and the dietary intakes in people with obesity: A randomized clinical trial

Payahoo, Laleh; Khajebishak, Yaser; Alivand, Mohammad Reza; Soleimanzade, Hamid; Alipour, Shahriar; Ostadrahimi, Alireza

doi:10.1016/j.appet.2019.05.032

Cited by 35 publications

(31 citation statements)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, Payahoo et al reported that supplementation with OEA (250 mg) in healthy obese subjects resulted in significant improvements in their appetite sensations (hunger and the desire to eat reduced, and fullness increased). In addition, a significant reduction in the energy and carbohydrate intakes was reported in OEA group compared to placebo group, even after adjusting for confounder factors . It is assumed that OEA regulates appetite in the central nervous system (CNS) by delivering hypothalamic neuropeptides involved in the regulation of energy homeostasis .…”

Section: Discussionmentioning

confidence: 99%

“…In addition, a significant reduction in the energy and carbohydrate intakes was reported in OEA group compared to placebo group, even after adjusting for confounder factors. 38 It is assumed that OEA regulates appetite in the central nervous system (CNS) by delivering hypothalamic neuropeptides involved in the regulation of energy homeostasis. 39 The hypophagic action of OEA is mediated by PPAR-α activation.…”

Section: Satiating Effects Of Oleoylethanolamidementioning

confidence: 99%

See 1 more Smart Citation

A systematic review of the effects of oleoylethanolamide, a high‐affinity endogenous ligand of PPAR‐α, on the management and prevention of obesity

Tutunchi

Saghafi-Asl

Ostadrahimi

2020

Clin Exp Pharma Physio

Self Cite

View full text Add to dashboard Cite

Along with an increase in overweight and obesity among all age groups, the development of efficacious and safe anti‐obesity strategies for patients, as well as health systems, is critical. Oleoylethanolamide (OEA), a high‐affinity endogenous ligand of nuclear receptor peroxisome proliferator‐activated receptor alpha (PPAR‐α), plays important physiological and metabolic actions. OEA is derived from oleic acid, a monounsaturated fatty acid, which has beneficial effects on body composition and regional fat distribution. The role of OEA in the modulation of food consumption and weight management makes it an attractive molecule requiring further exploration in obesogenic environments. This systematic review was conducted to assess the effects of OEA on the obesity management, with emphasizing on its physiological roles and possible mechanisms of action in energy homeostasis. We searched PubMed/Medline, Google Scholar, ScienceDirect, Scopus, ProQuest, and EMBASE up until September 2019. Out of 712 records screened, 30 articles met the study criteria. The evidence reviewed here indicates that OEA, an endocannabinoid‐like compound, leads to satiation or meal termination through PPAR‐α activation and fatty acid translocase (FAT)/CD36. Additionally, the lipid‐amide OEA stimulates fatty acid uptake, lipolysis, and beta‐oxidation, and also promotes food intake control. OEA also exerts satiety‐inducing effects by activating the hedonic dopamine pathways and increasing homeostatic oxytocin and brain histamine. In conclusion, OEA may be a key component of the physiological system involved in the regulation of dietary fat consumption and energy homeostasis; therefore, it is suggested as a possible therapeutic agent for the management of obesity.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Satiating Effects Of Oleoylethanolamidementioning

confidence: 99%

A systematic review of the effects of oleoylethanolamide, a high‐affinity endogenous ligand of PPAR‐α, on the management and prevention of obesity

Tutunchi

Saghafi-Asl

Ostadrahimi

2020

Clin Exp Pharma Physio

Self Cite

View full text Add to dashboard Cite

show abstract

“…Further studies have also shown that alteration of microbial diversity may lead to metabolic changes 46,47 . Specifically, it has been reported that Bacteroides perform efficient hydrolysis of Rebaudioside A to steviol 34 and there are even reports of an inverse relation with abundance of Akkermansia and the body weight of mice and humans 48,49 . Our study preliminarily found that the ratio between Akkermansia and Bacteroides was potentially improved by Rebaudioside A as compared to HFHC, which is intriguing and can be a potential focus of future research.…”

Section: Discussionmentioning

confidence: 99%

Rebaudioside affords hepatoprotection ameliorating sugar sweetened beverage- induced nonalcoholic steatohepatitis

Xi¹,

Bhattacharjee²,

Salazar-González³

et al. 2020

Sci Rep

View full text Add to dashboard Cite

Sugar-sweetened beverage consumption is a known independent risk factor for nonalcoholic steatohepatitis (NASH). Non-caloric sweeteners (NCS) are food additives providing sweetness without calories and are considered safe and/or not metabolized by the liver. The potential role of newer NCS in the regulation of NASH, however, remain unknown. Our study aimed to determine the impact of newer NCS including Rebaudioside A and sucralose on NASH using high fat diet induced obesity mouse model by substituting fructose and sucrose with NCS in the drinking water. We characterized the phenotype of NCS-treated obesity and investigated the alterations of hepatic function and underlying mechanisms. We found that NCS have no impact on weight gain and energy balance in high fat diet induced obesity. However, in comparison to fructose and sucrose, Rebaudioside A significantly improved liver enzymes, hepatic steatosis and hepatic fibrosis. Additionally, Rebaudioside A improved endoplasmic reticulum (ER) stress related gene expressions, fasting glucose levels, insulin sensitivity and restored pancreatic islet cell mass, neuronal innervation and microbiome composition. We concluded that Rebaudioside A significantly ameliorated murine NASH, while the underlying mechanisms requires further investigation. Current treatment strategies for nonalcoholic steatohepatitis (NASH) have focused on lifestyle management of modifiable risk factors, through a combination of diet and exercise 1-3. Potential therapeutic targets for NASH intersect with the complex pathogenesis of NASH including hepatic steatosis from the imbalance of lipogenesis and free fatty acid (FFA) promoting inflammatory response and fibrosis progression 4,5. However, despite pharmaceutical agents currently in advanced stages of clinical testing 6-8 , NASH is on track predicted to become the main reason for liver transplant in the very near future 9. Therefore, it is essential to continue to explore novel NASH therapies. Sugar sweetened beverages are now well acknowledged to have severe consequences on human health. Consequently, non-caloric sweeteners (NCS) such as aspartame, sucralose, saccharin, and Rebaudioside A have increased in popularity and usage. However, there is a limited evidence for the benefits of frequent consumption of NCS sugar substitutes. This is especially true for the most recent addition Rebaudioside A, that is an extract of the stevia leaf that provides sweetness without calories 10. Interestingly, recent literature has reported that Rebaudioside A may in fact play a role in glucose metabolism and has even been reported to improve post-prandial glucose-insulin index 11 , and its consumption may result in weight loss in mice fed a high fat diet 12. These observations suggest a potential role for Rebaudioside A on glucose metabolism in general, and on liver function and NASH in particular. The well-known interactions between human health, diet and intestinal microbiota are based on the involvement of the microbiome in metabolism and immunity, which also par...

show abstract

“…Oleoylethanolamide (OEA) is an endogenous fatty acid ethanolamide belonging to the N-acylethanolamine family. OEA is contained in foods such as nuts, cocoa powder, and oatmeal ( Payahoo et al., 2019 ), and has been found in different tissues such as the gastrointestinal tract, muscle, adipocytes, liver, kidney, heart, lung, pancreas, brain, salivary gland, and reproductive tract ( Ambrosini et al., 2006 ; Tutunchi et al., 2020 ). OEA activates peroxisome proliferator-activated receptor (PPAR)-α, G protein-coupled receptor (GPR) 119, and transient receptor potential vanilloid (TRPV) 1 ( Brown et al, 2016 ).…”

Section: Introductionmentioning

confidence: 99%

Oleoylethanolamide Ameliorates Dextran Sulfate Sodium-Induced Colitis in Rats

et al. 2020

View full text Add to dashboard Cite

Oleoylethanolamide (OEA) is an endogenous fatty acid ethanolamide known for its antiinflammatory effects and its influence on gut microbiota composition; however, the effects of OEA in inflammatory bowel disease (IBD) remain unknown. During in vitro experiments, OEA downregulated the expression of tumor necrosis factor (TNF)-a and reduced phosphorylation of inhibitor of kappa (Ik) Ba induced by lipopolysaccharide in human embryonic kidney cells. Moreover, OEA downregulated the expression of interleukin (IL)-8 and IL-1b and inhibited the phosphorylation of IkBa and p65 induced by TNF-a in human enterocytes (Caco-2). The effect of OEA in reducing the expression of IL-8 was blocked by the peroxisome proliferator-activated receptor (PPAR)-a antagonist. During in vivo experiments on rats, colitis was induced by the oral administration of 8% dextran sulfate sodium from day 0 through day 5, and OEA (20 mg/kg) was intraperitoneally injected once a day from day 0 for 6 days. OEA administration significantly ameliorated the reduction in body weight, the increase in disease activity index score, and the shortening of colon length. In rectums, OEA administration reduced the infiltration of macrophages and neutrophils and tended to reduce the histological score and the expression of inflammatory cytokines. Administration of OEA produced significant improvement in a colitis model, possibly by inhibiting the nuclear factor kappa B signaling pathway through PPAR-a receptors. OEA could be a potential new treatment for IBD.

show abstract

Investigation the effect of oleoylethanolamide supplementation on the abundance of Akkermansia muciniphila bacterium and the dietary intakes in people with obesity: A randomized clinical trial

Cited by 35 publications

References 66 publications

A systematic review of the effects of oleoylethanolamide, a high‐affinity endogenous ligand of PPAR‐α, on the management and prevention of obesity

A systematic review of the effects of oleoylethanolamide, a high‐affinity endogenous ligand of PPAR‐α, on the management and prevention of obesity

Rebaudioside affords hepatoprotection ameliorating sugar sweetened beverage- induced nonalcoholic steatohepatitis

Oleoylethanolamide Ameliorates Dextran Sulfate Sodium-Induced Colitis in Rats

Contact Info

Product

Resources

About